Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication. | Alector’s Abbvie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study,

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech expects its current cash position to last it through 2026.

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's disease. Its drug failed the Phase 2 trial.